Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BXM7

UPID:
PINK1_HUMAN

ALTERNATIVE NAMES:
BRPK; PTEN-induced putative kinase protein 1

ALTERNATIVE UPACC:
Q9BXM7; Q8N6T9; Q8NBU3; Q96DE4

BACKGROUND:
The Serine/threonine-protein kinase PINK1, mitochondrial, known alternatively as BRPK or PTEN-induced putative kinase protein 1, is crucial for mitochondrial maintenance. It phosphorylates mitochondrial proteins like PRKN and DNM1L under stress, facilitating mitochondrial quality control by removing or replacing damaged components. This process ranges from apoptosis prevention and mitochondrial biogenesis stimulation to mitochondrial dynamics regulation and damaged mitochondria clearance through mitophagy.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in the pathogenesis of Parkinson disease 6, a neurodegenerative disorder with mitochondrial depolarization and dysfunction, PINK1 represents a promising target for therapeutic intervention. The exploration of PINK1's functions and mechanisms offers a pathway to novel treatments for Parkinson's disease, highlighting the importance of mitochondrial quality control in neurodegeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.